The RNAi pathway was first discovered in Caenorhabditis elegans; injection of double-stranded (ds) RNA into the worm initiated sequence-specific degradation of mRNAs that contain the same sequence ...

interferon pathway machinery) or nontargeted mRNAs. As a result, the standard of care to demonstrate the specificity of an observed RNAi-induced phenotype (namely the suppression of the targeted ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of ...

The natural RNAi mechanism can be directed by either short interfering RNA (siRNA) or microRNA (miRNA). 1 There are four key steps in the RNAi pathway. When miRNA acts as the guide for RNAi, only a ...

The discovery of RNAi dates back to the 1990s when researchers observed unexpected gene silencing in plants and fungi. In 1998, Andrew Fire and Craig Mello published a groundbreaking study ...

Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigational RNA interference (RNAi) candidate was ...

Since its discovery 16 years ago, researchers have been eyeing RNA interference (RNAi)—a natural process of posttranscriptional silencing of genes by small fragments of the nucleic acid—for its ...

Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released topline results from Part 2 of a Phase 1/2 study of ARO-C3, the ...

The presentation titled, "Targeting Obesity with RNAi-based Therapies," was included ... both seek to intervene in a known biological pathway with strong support from human genetics studies ...

The company's Targeted RNAi Molecule (TRiM ... a ligand and ARO-ALK7 inhibiting a receptor to intervene in a known pathway that signals the body to store fat in adipose tissue.